Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response-Reference-Cited by-同舟云学术

Anti–miR-93-5p therapy prolongs sepsis survival by restoring the peripheral immune response

Published:2023-07-17 Issue:14 Volume:133 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Dragomir Mihnea P.^ORCID,Fuentes-Mattei Enrique^ORCID,Winkle Melanie^ORCID,Okubo Keishi,Bayraktar Recep^ORCID,Knutsen Erik^ORCID,Qdaisat Aiham^ORCID,Chen Meng,Li Yongfeng,Shimizu Masayoshi,Pang Lan,Liu Kevin^ORCID,Liu Xiuping,Anfossi Simone^ORCID,Zhang Huanyu^ORCID,Koch Ines,Tran Anh M.,Mohapatra Swati^ORCID,Ton Anh,Kaplan Mecit^ORCID,Anderson Matthew W.^ORCID,Rothfuss Spencer J.,Silasi Robert^ORCID,Keshari Ravi S.,Ferracin Manuela,Ivan Cristina,Rodriguez-Aguayo Cristian^ORCID,Lopez-Berestein Gabriel,Georgescu Constantin,Banerjee Pinaki P.,Basar Rafet^ORCID,Li Ziyi^ORCID,Horst David^ORCID,Vasilescu Catalin,Bertilaccio Maria Teresa S.^ORCID,Rezvani Katayoun^ORCID,Lupu Florea^ORCID,Yeung Sai-Ching^ORCID,Calin George A.^ORCID

Funder

CPRIT Research Training Program

Charité – Universitätsmedizin Berlin and the Berlin Institute of Health

The Northern Norway Regional Health Authority

National Institutes of Health

National Cancer Institute

NIGMS

U.S. Department of Defense

DKTK Berlin

Northern Norway Regional Health Authority

Publisher

American Society for Clinical Investigation